STOCK TITAN

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Bioventus CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Positive
  • None.
Negative
  • None.

DURHAM, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Tony Bihl, interim chief executive officer, will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on Wednesday, September 13, 2023, at 8:50 a.m. ET.

A live audio webcast of the fireside chat will be available on the “Investors” section of the Company’s website at www.bioventus.com and will be available for replay on that site following the event.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Contact:
Dave Crawford
919-474-6787
dave.crawford@bioventus.com


Bioventus Inc.

NASDAQ:BVS

BVS Rankings

BVS Latest News

BVS Stock Data

253.40M
23.20M
11.14%
66.3%
0.99%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
DURHAM

About BVS

bioventus® is a global leader in orthobiologics and its mission is to make a difference by helping patients resume and enjoy active lives. bioventus accomplishes this with its orthobiologic products for musculoskeletal healing, regeneration and related biosurgery that engage and enhance the body’s natural healing processes. the company has two product portfolios for orthobiologics, bioventus active healing therapies and bioventus surgical, which are created through a combination of internal product development, product/business acquisition, and distribution agreements. established in 2012, bioventus is privately held and headquartered in durham, nc. the company has nearly 600 employees worldwide and its international headquarters is in hoofddorp, the netherlands. bioventus also has offices in memphis, tn, australia and canada, and a research and development site is located in boston. bioventus works with patients, payers and health care providers throughout the world, and generat